Sol-Gel Technologies Ltd. (SLGL)

NASDAQ: SLGL · IEX Real-Time Price · USD
1.070
-0.020 (-1.83%)
Feb 27, 2024, 10:39 AM EST - Market open
-1.83%
Market Cap 30.28M
Revenue (ttm) 1.67M
Net Income (ttm) -27.73M
Shares Out 27.86M
EPS (ttm) -1.09
PE Ratio n/a
Forward PE 9.34
Dividend n/a
Ex-Dividend Date n/a
Volume 4,715
Open 1.070
Previous Close 1.090
Day's Range 1.058 - 1.110
52-Week Range 0.900 - 4.658
Beta 1.42
Analysts Strong Buy
Price Target 8.00 (+647.66%)
Earnings Date Mar 12, 2024

About SLGL

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosac... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 23, 2018
Employees 55
Stock Exchange NASDAQ
Ticker Symbol SLGL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for SLGL stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 647.66% from the latest price.

Price Target
$8.0
(647.66% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

NESS ZIONA, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for...

3 months ago - GlobeNewsWire

Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

NESS ZIONA, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for...

3 months ago - GlobeNewsWire

Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update

NESS ZIONA, Israel, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for...

3 months ago - GlobeNewsWire

Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

NESS ZIONA, Israel, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients wi...

6 months ago - GlobeNewsWire

Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update

NESS ZIONA, Israel, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for...

7 months ago - GlobeNewsWire

Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada

NESS ZIONA, Israel & MONTREAL--(BUSINESS WIRE)--Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel”), an Israel-based dermatology company and Searchlight Pharma Inc. (“Searchlight”), a private Canadi...

9 months ago - Business Wire

Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products, EPSOLAY and TWYNEO, that were launched i...

10 months ago - GlobeNewsWire

Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an i...

1 year ago - GlobeNewsWire

Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

NESS ZIONA, Israel, March 10, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an i...

1 year ago - GlobeNewsWire

Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings

NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two inn...

1 year ago - GlobeNewsWire

Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million

NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) --  Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two innovative dermatology products...

1 year ago - GlobeNewsWire

Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and gen...

1 year ago - GlobeNewsWire

Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

NESS ZIONA, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and gen...

1 year ago - GlobeNewsWire

Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

NESS ZIONA, Israel, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and gen...

1 year ago - GlobeNewsWire

Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update

NESS ZIONA, Israel, May 13, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and gene...

1 year ago - GlobeNewsWire

Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®

NESS ZIONA, Israel and ZUG, Switzerland, April 25, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing bran...

2 years ago - GlobeNewsWire

Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®

NESS ZIONA, Israel, April 14, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topic...

2 years ago - GlobeNewsWire

Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments

NESS ZIONA, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topic...

2 years ago - GlobeNewsWire

Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA

TWYNEO will be officially launched for commercial availability in Spring 2022. TWYNEO will be officially launched for commercial availability in Spring 2022.

2 years ago - GlobeNewsWire

Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference

NESS ZIONA, Israel, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and...

2 years ago - GlobeNewsWire

Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®

NESS ZIONA, Israel, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topica...

2 years ago - GlobeNewsWire

Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments

NESS ZIONA, Israel, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topica...

2 years ago - GlobeNewsWire

Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference

NESS ZIONA, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topica...

2 years ago - GlobeNewsWire

Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference

NESS ZIONA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topic...

2 years ago - GlobeNewsWire

Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference

NESS ZIONA, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topic...

2 years ago - GlobeNewsWire